Gainers

• Can Fite Biopharma (AMEX:CANF) stock rose 17.6% to $5.88 during Wednesday's pre-market session. The market value of their outstanding shares is at $6.5 million.
• Evolus (NASDAQ:EOLS) stock moved upwards by 14.76% to $4.74. The market value of their outstanding shares is at $267.7 million. The company's, Q4 earnings came out yesterday.
• Reviva Pharmaceuticals (NASDAQ:RVPH) stock moved upwards by 11.47% to $0.24. The market value of their outstanding shares is at $25.1 million.
• 20/20 Biolabs (NASDAQ:AIDX) stock rose 11.18% to $3.28. The market value of their outstanding shares is at $30.5 million.
• Kala Bio (NASDAQ:KALA) stock moved upwards by 10.92% to $0.39. The company's market cap stands at $319.6 million.
• Medicus Pharma (NASDAQ:MDCX) stock moved upwards by 9.52% to $1.61. The market value of their outstanding shares is at $36.3 million.

Losers

• SCWorx (NASDAQ:WORX) shares declined by 44.1% to $0.1 during Wednesday's pre-market session. The company's market cap stands at $2.8 million.
• Matinas BioPharma Hldgs (AMEX:MTNB) stock fell 16.33% to $0.51. The company's market cap stands at $3.8 million.
• XORTX Therapeutics (NASDAQ:XRTX) stock declined by 16.24% to $0.33. The market value of their outstanding shares is at $2.7 million.
• Innovative Eyewear (NASDAQ:LUCY) shares decreased by 11.51% to $1.0. The market value of their outstanding shares is at $6.0 million.
• Staar Surgical (NASDAQ:STAA) shares decreased by 10.15% to $17.0. The company's market cap stands at $934.0 million. The company's, Q4 earnings came out yesterday.
• SILO Pharma (NASDAQ:SILO) shares decreased by 9.93% to $0.34. The company's market cap stands at $5.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.